Literature DB >> 24749746

Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.

P J Schuler1, Z Saze, C-S Hong, L Muller, D G Gillespie, D Cheng, M Harasymczuk, M Mandapathil, S Lang, E K Jackson, T L Whiteside.   

Abstract

While murine CD4(+) CD39(+) regulatory T cells (T(reg)) co-express CD73 and hydrolyze exogenous (e) adenosine triphosphate (ATP) to immunosuppressive adenosine (ADO), surface co-expression of CD73 on human circulating CD4(+) CD39(+) T(reg) is rare. Therefore, the ability of human T(reg) to produce and utilize ADO for suppression remains unclear. Using mass spectrometry, we measured nucleoside production by subsets of human CD4(+) CD39(+) and CD4(+) CD39(-)CD73(+) T cells or CD19(+) B cells isolated from blood of 30 volunteers and 14 cancer patients. CD39 and CD73 expression was evaluated by flow cytometry, Western blots, confocal microscopy or reverse transcription-polymerase chain reaction (RT-PCR). Circulating CD4(+) CD39(+) T(reg) which hydrolyzed eATP to 5'-AMP contained few intracytoplasmic granules and had low CD73 mRNA levels. Only ∼1% of these T(reg) were CD39(+) CD73(+) . In contrast, CD4(+) CD39(neg) CD73(+) T cells contained numerous CD73(+) granules in the cytoplasm and strongly expressed surface CD73. In vitro-generated T(reg) (Tr1) and most B cells were CD39(+) CD73(+) . All these CD73(+) T cell subsets and B cells hydrolyzed 5'-AMP to ADO. Exosomes isolated from plasma of normal control (NC) or cancer patients carried enzymatically active CD39 and CD73(+) and, when supplied with eATP, hydrolyzed it to ADO. Only CD4(+) CD39(+) T(reg) co-incubated with CD4(+) CD73(+) T cells, B cells or CD39(+) CD73(+) exosomes produced ADO. Thus, contact with membrane-tethered CD73 was sufficient for ADO production by CD4(+) CD39(+) T(reg). In microenvironments containing CD4(+) CD73(+) T cells, B cells or CD39(+) CD73(+) exosomes, CD73 is readily available to CD4(+) CD39(+) CD73(neg) T(reg) for the production of immunosuppressive ADO.
© 2014 British Society for Immunology.

Entities:  

Keywords:  adenosine; ectonucleotidases; exosomes; human tTreg; immune suppression; pTreg

Mesh:

Substances:

Year:  2014        PMID: 24749746      PMCID: PMC4226604          DOI: 10.1111/cei.12354

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  41 in total

1.  Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells.

Authors:  Thomas Duhen; Rebekka Duhen; Antonio Lanzavecchia; Federica Sallusto; Daniel J Campbell
Journal:  Blood       Date:  2012-03-21       Impact factor: 22.113

2.  A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells.

Authors:  Paul E Zarek; Ching-Tai Huang; Eric R Lutz; Jeanne Kowalski; Maureen R Horton; Joel Linden; Charles G Drake; Jonathan D Powell
Journal:  Blood       Date:  2007-10-01       Impact factor: 22.113

3.  AMP is an adenosine A1 receptor agonist.

Authors:  Joseph E Rittiner; Ilia Korboukh; Emily A Hull-Ryde; Jian Jin; William P Janzen; Stephen V Frye; Mark J Zylka
Journal:  J Biol Chem       Date:  2012-01-03       Impact factor: 5.157

4.  CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice.

Authors:  Long Wang; Jie Fan; Linda F Thompson; Yi Zhang; Tahiro Shin; Tyler J Curiel; Bin Zhang
Journal:  J Clin Invest       Date:  2011-05-02       Impact factor: 14.808

5.  Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes.

Authors:  Jeong Whun Kim; Eva Wieckowski; Douglas D Taylor; Torsten E Reichert; Simon Watkins; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2005-02-01       Impact factor: 12.531

6.  CD39/NTPDase-1 activity and expression in normal leukocytes.

Authors:  E Dianne Pulte; M Johan Broekman; Kim E Olson; Joan H F Drosopoulos; Jorge R Kizer; Naziba Islam; Aaron J Marcus
Journal:  Thromb Res       Date:  2007-06-07       Impact factor: 3.944

7.  Regulatory T cells: recommendations to simplify the nomenclature.

Authors:  Abul K Abbas; Christophe Benoist; Jeffrey A Bluestone; Daniel J Campbell; Sankar Ghosh; Shohei Hori; Shuiping Jiang; Vijay K Kuchroo; Diane Mathis; Maria Grazia Roncarolo; Alexander Rudensky; Shimon Sakaguchi; Ethan M Shevach; Dario A A Vignali; Steve F Ziegler
Journal:  Nat Immunol       Date:  2013-04       Impact factor: 25.606

8.  Tumor antigen specific iTreg accumulate in the tumor microenvironment and suppress therapeutic vaccination.

Authors:  Taylor H Schreiber; Dietlinde Wolf; Maria Bodero; Eckhard Podack
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

9.  The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway.

Authors:  Akio Ohta; Radhika Kini; Akiko Ohta; Meenakshi Subramanian; Manasa Madasu; Michail Sitkovsky
Journal:  Front Immunol       Date:  2012-07-05       Impact factor: 7.561

Review 10.  Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape.

Authors:  François Ghiringhelli; Mélanie Bruchard; Fanny Chalmin; Cédric Rébé
Journal:  J Biomed Biotechnol       Date:  2012-10-14
View more
  110 in total

1.  Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer.

Authors:  Sonja Ludwig; Theofanis Floros; Marie-Nicole Theodoraki; Chang-Sook Hong; Edwin K Jackson; Stephan Lang; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2017-04-11       Impact factor: 12.531

Review 2.  Type 1 regulatory T cells: a new mechanism of peripheral immune tolerance.

Authors:  Hanyu Zeng; Rong Zhang; Boquan Jin; Lihua Chen
Journal:  Cell Mol Immunol       Date:  2015-06-08       Impact factor: 11.530

3.  CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.

Authors:  Shi Yong Neo; Ying Yang; Julien Record; Ran Ma; Xinsong Chen; Ziqing Chen; Nicholas P Tobin; Emily Blake; Christina Seitz; Ron Thomas; Arnika Kathleen Wagner; John Andersson; Jana de Boniface; Jonas Bergh; Shannon Murray; Evren Alici; Richard Childs; Martin Johansson; Lisa S Westerberg; Felix Haglund; Johan Hartman; Andreas Lundqvist
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 4.  Adenosine signaling and adenosine deaminase regulation of immune responses: impact on the immunopathogenesis of HIV infection.

Authors:  Daniela F Passos; Viviane M Bernardes; Jean L G da Silva; Maria R C Schetinger; Daniela Bitencourt Rosa Leal
Journal:  Purinergic Signal       Date:  2018-08-10       Impact factor: 3.765

5.  Anti-CD73 in cancer immunotherapy: awakening new opportunities.

Authors:  Luca Antonioli; Gennady G Yegutkin; Pál Pacher; Corrado Blandizzi; György Haskó
Journal:  Trends Cancer       Date:  2016-02-01

Review 6.  Tumor-Derived Exosomes and Their Role in Cancer Progression.

Authors:  Theresa L Whiteside
Journal:  Adv Clin Chem       Date:  2016-04-07       Impact factor: 5.394

Review 7.  A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer.

Authors:  Stephen M Hatfield; Michail Sitkovsky
Journal:  Curr Opin Pharmacol       Date:  2016-07-17       Impact factor: 5.547

8.  Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells.

Authors:  Yuliia Kaljas; Chengqian Liu; Maksym Skaldin; Chengxiang Wu; Qing Zhou; Yuanan Lu; Ivona Aksentijevich; Andrey V Zavialov
Journal:  Cell Mol Life Sci       Date:  2016-09-23       Impact factor: 9.261

Review 9.  Induced regulatory T cells in inhibitory microenvironments created by cancer.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2014-06-17       Impact factor: 4.388

Review 10.  The potential of tumor-derived exosomes for noninvasive cancer monitoring.

Authors:  Theresa L Whiteside
Journal:  Expert Rev Mol Diagn       Date:  2015-08-02       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.